0 138

Cited 3 times in

Cosmetic Outcome and Toxicity After Stereotactic Accelerated Partial Breast Irradiation in Early Breast Cancer: A Prospective Observational Cohort Study

DC Field Value Language
dc.contributor.author김용배-
dc.contributor.author김지훈-
dc.contributor.author김호진-
dc.contributor.author변화경-
dc.contributor.author장지석-
dc.contributor.author한민철-
dc.date.accessioned2024-01-03T00:53:23Z-
dc.date.available2024-01-03T00:53:23Z-
dc.date.issued2023-11-
dc.identifier.issn0360-3016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/197402-
dc.description.abstractPurpose: The aim of this work was to prospectively evaluate the toxicity and cosmetic outcomes of 5-fraction, stereotactic, accelerated partial breast irradiation (APBI). Methods and materials: This prospective observational cohort study enrolled women who underwent APBI for invasive carcinoma or carcinoma in situ of the breast. APBI was delivered using a CyberKnife M6 robotic radiosurgery system at 30 Gy in 5 nonconsecutive, once-daily fractions. Women undergoing whole breast irradiation (WBI) were also enrolled for comparison. Patient-reported and physician-assessed adverse events were recorded. Breast fibrosis was measured using a tissue compliance meter, and breast cosmesis was assessed using BCCT.core (an automatic, computer-based software). Outcomes were collected until 24 months posttreatment according to the study protocol. Results: In total, 204 patients (APBI, n = 103; WBI, n = 101) were enrolled. Regarding patient-reported outcomes, the APBI group reported significantly less skin dryness (6.9% vs 18.3%; P = .015), radiation skin reaction (9.9% vs 23.5%; P = .010), and breast hardness (8.0% vs 20.4%; P = .011) at 6 months than the WBI group. On physician assessment, the APBI group had significantly less dermatitis at 12 months (1.0% vs 7.2%; P = .027) than the WBI group. Any severe toxicities after APBI were rare in patient-reported outcomes (score ≥3, 3.0%) and physician assessments (grade ≥3, 2.0%). In the uninvolved quadrants, measured fibrosis in the APBI group was significantly lower than that in the WBI group at 6 (P = .001) and 12 (P = .029) months but not at 24 months. In the involved quadrant, measured fibrosis in the APBI group was not significantly different from that in the WBI group at any time. Cosmetic outcomes in the APBI group were mostly excellent or good (77.6%) at 24 months, and there was no significant cosmetic detriment from the baseline. Conclusions: Stereotactic APBI was associated with less fibrosis in the uninvolved breast quadrants than WBI. Patients showed minimal toxicity and no detrimental effects on cosmesis after APBI.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Science Inc.-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHBreast / radiation effects-
dc.subject.MESHBreast Neoplasms* / pathology-
dc.subject.MESHBreast Neoplasms* / radiotherapy-
dc.subject.MESHBreast Neoplasms* / surgery-
dc.subject.MESHCarcinoma in Situ* / surgery-
dc.subject.MESHFemale-
dc.subject.MESHFibrosis-
dc.subject.MESHHumans-
dc.subject.MESHMastectomy, Segmental-
dc.subject.MESHProspective Studies-
dc.subject.MESHTreatment Outcome-
dc.titleCosmetic Outcome and Toxicity After Stereotactic Accelerated Partial Breast Irradiation in Early Breast Cancer: A Prospective Observational Cohort Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorHwa Kyung Byun-
dc.contributor.googleauthorJee Suk Chang-
dc.contributor.googleauthorHojin Kim-
dc.contributor.googleauthorJihun Kim-
dc.contributor.googleauthorMin Cheol Han-
dc.contributor.googleauthorSe Young Kim-
dc.contributor.googleauthorRyeong Hwang Park-
dc.contributor.googleauthorClaire Jieun Kim-
dc.contributor.googleauthorYong Bae Kim-
dc.identifier.doi10.1016/j.ijrobp.2023.05.018-
dc.contributor.localIdA00744-
dc.contributor.localIdA05823-
dc.contributor.localIdA05970-
dc.contributor.localIdA05136-
dc.contributor.localIdA04658-
dc.contributor.localIdA05870-
dc.relation.journalcodeJ01157-
dc.identifier.eissn1879-355X-
dc.identifier.pmid37201757-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0360301623004649-
dc.contributor.alternativeNameKim, Yong Bae-
dc.contributor.affiliatedAuthor김용배-
dc.contributor.affiliatedAuthor김지훈-
dc.contributor.affiliatedAuthor김호진-
dc.contributor.affiliatedAuthor변화경-
dc.contributor.affiliatedAuthor장지석-
dc.contributor.affiliatedAuthor한민철-
dc.citation.volume117-
dc.citation.number3-
dc.citation.startPage690-
dc.citation.endPage700-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.117(3) : 690-700, 2023-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.